Synthetic biodegradable microparticle and nanoparticle vaccines against the respiratory syncytial virus

Patricia A. Jorquera; Ralph A. Tripp

doi:10.3390/vaccines4040045

Synthetic biodegradable microparticle and nanoparticle vaccines against the respiratory syncytial virus

Patricia A. Jorquera, Ralph A. Tripp

Research output: Contribution to journal › Review article › peer-review

28 Citations (Scopus)

35 Downloads (Pure)

Abstract

Synthetic biodegradable microparticle and nanoparticle platform technology provides the opportunity to design particles varying in composition, size, shape and surface properties for application in vaccine development. The use of particle vaccine formulations allows improvement of antigen stability and immunogenicity while allowing targeted delivery and slow release. This technology has been design to develop novel vaccines against the respiratory syncytial virus (RSV), the leading cause of lower respiratory tract infection in infants. In the last decade, several nano-and micro-sized RSV vaccine candidates have been developed and tested in animal models showing promising results. This review provides an overview of recent advances in prophylactic particle vaccines for RSV and the multiple factors that can affect vaccine efficacy.

Original language	English
Article number	45
Pages (from-to)	1-14
Number of pages	14
Journal	Vaccines
Volume	4
Issue number	4
DOIs	https://doi.org/10.3390/vaccines4040045
Publication status	Published - 2 Dec 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/vaccines4040045Licence: CC BY

ArticleFinal published version, 1.28 MBLicence: CC BY

Cite this

@article{71b0df4fe9e84cad8605a3e9b022292a,

title = "Synthetic biodegradable microparticle and nanoparticle vaccines against the respiratory syncytial virus",

abstract = "Synthetic biodegradable microparticle and nanoparticle platform technology provides the opportunity to design particles varying in composition, size, shape and surface properties for application in vaccine development. The use of particle vaccine formulations allows improvement of antigen stability and immunogenicity while allowing targeted delivery and slow release. This technology has been design to develop novel vaccines against the respiratory syncytial virus (RSV), the leading cause of lower respiratory tract infection in infants. In the last decade, several nano-and micro-sized RSV vaccine candidates have been developed and tested in animal models showing promising results. This review provides an overview of recent advances in prophylactic particle vaccines for RSV and the multiple factors that can affect vaccine efficacy.",

keywords = "Microparticle, Nanoparticle, RSV, Vaccine, VLPs",

author = "Jorquera, {Patricia A.} and Tripp, {Ralph A.}",

note = "Publisher Copyright: {\textcopyright} 2016 by the authors; licensee MDPI, Basel, Switzerland.",

year = "2016",

month = dec,

day = "2",

doi = "10.3390/vaccines4040045",

language = "English",

volume = "4",

pages = "1--14",

journal = "Vaccines",

issn = "2076-393X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "4",

}

TY - JOUR

T1 - Synthetic biodegradable microparticle and nanoparticle vaccines against the respiratory syncytial virus

AU - Jorquera, Patricia A.

AU - Tripp, Ralph A.

PY - 2016/12/2

Y1 - 2016/12/2

N2 - Synthetic biodegradable microparticle and nanoparticle platform technology provides the opportunity to design particles varying in composition, size, shape and surface properties for application in vaccine development. The use of particle vaccine formulations allows improvement of antigen stability and immunogenicity while allowing targeted delivery and slow release. This technology has been design to develop novel vaccines against the respiratory syncytial virus (RSV), the leading cause of lower respiratory tract infection in infants. In the last decade, several nano-and micro-sized RSV vaccine candidates have been developed and tested in animal models showing promising results. This review provides an overview of recent advances in prophylactic particle vaccines for RSV and the multiple factors that can affect vaccine efficacy.

AB - Synthetic biodegradable microparticle and nanoparticle platform technology provides the opportunity to design particles varying in composition, size, shape and surface properties for application in vaccine development. The use of particle vaccine formulations allows improvement of antigen stability and immunogenicity while allowing targeted delivery and slow release. This technology has been design to develop novel vaccines against the respiratory syncytial virus (RSV), the leading cause of lower respiratory tract infection in infants. In the last decade, several nano-and micro-sized RSV vaccine candidates have been developed and tested in animal models showing promising results. This review provides an overview of recent advances in prophylactic particle vaccines for RSV and the multiple factors that can affect vaccine efficacy.

KW - Microparticle

KW - Nanoparticle

KW - RSV

KW - Vaccine

KW - VLPs

UR - http://www.scopus.com/inward/record.url?scp=85018185377&partnerID=8YFLogxK

U2 - 10.3390/vaccines4040045

DO - 10.3390/vaccines4040045

M3 - Review article

AN - SCOPUS:85018185377

SN - 2076-393X

VL - 4

SP - 1

EP - 14

JO - Vaccines

JF - Vaccines

IS - 4

M1 - 45

ER -

Synthetic biodegradable microparticle and nanoparticle vaccines against the respiratory syncytial virus

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this